1. Introduction {#s0005}
===============

Spinal cord injury (SCI) is a serious central nervous system (CNS) injury resulting in a variety of complications including paralysis, sensory deficits and motor dysfunctions ([@b0040]). In 1996, endogenous neural stem/progenitor cells (eNSPCs) have been found in adult human spinal cord ([@b0130]). In addition, the previous study has shown that eNSPCs transplantation may be potentially beneficial for functional recovery of patients after SCI ([@b0070]).

Melatonin, as a neurohormone, is synthesized and secreted from the pineal gland ([@b0125]). Recently, a variety of studies demonstrated that melatonin enhances adult stem cell viability, proliferation, and differentiation ([@b0095]), suggesting that melatonin may play an important role in regulating neurogenesis of eNSPCs in CNS. In addition, [@b0035] have shown that melatonin stimulates eNSPCs proliferation and differentiation *in vitro*.

To the best of our knowledge, there is no study assessing the effects of melatonin on eNSPCs proliferation and differentiation after SCI *in vivo*. Therefore, we used SCI rat model to evaluate melatonin treatment effects.

2. Methods {#s0010}
==========

2.1. Experimental animals {#s0015}
-------------------------

A total of 40 male 8-week-old Sprague-Dawley rats averagely weighting 250--270 g were enrolled in the present study. Ten of them developed health problems or died after SCI. The remaining 20 rats were used for further study. The 20 rats were randomly divided into three groups including the SCI group, the control group, and the melatonin treatment group.

2.2. SCI rat model {#s0020}
------------------

As described previously ([@b0080]), a contusive injury was performed. In brief, the T10 level was exposed with T9 laminectomy. Then, a rod weighting 10 g was lowered from 25 mm to the back surface of the spinal cord.

2.3. Melatonin treatment {#s0025}
------------------------

As described previously ([@b0080]), the melatonin treatment group rats were subcutaneously injected with melatonin (Sigma, St. Louis, MO, USA) twice a day at doses of 10 mg/kg body until the end of the experiment. Rats in the control group were injected subcutaneously with normal saline (Sigma, St. Louis, MO, USA) at the same dosage.

2.4. Assessment of motor function {#s0030}
---------------------------------

Motor function was evaluated with the BBB scale ([@b0010]) on postoperative days 1, 3, 7, 14, and 21.

2.5. Bromodeoxyuridine (BrdU) injection {#s0035}
---------------------------------------

Two days before the end of the experiment, rats were injected intraperitoneally with BrdU (Sigma, St. Louis, MO, USA) at doses of 50 mg/kg body weight once a day in order to label proliferating cells.

2.6. Tissue processing and immunohistochemistry {#s0040}
-----------------------------------------------

After assessment of motor function, rats were anesthetized and perfused using 4% PFA in 0.1 M PBS for 15 min. Then, mouse monoclonal anti-BrdU and rabbit polyclonal anti-Nestin were used to incubate with tissue at 4 °C. The slides were then incubated with goat anti-mouse antibody for 1 h.

2.7. Flow cytometry {#s0045}
-------------------

Spinal cord tissue (T8-T10) was collected and dissociated in trypsin (0.5 mg/ml) and collagenase (0.5 mg/ml). The spinal cord cells were then incubated in 0.5 ml of 2 M HCl and 0.5% IFS for 20 min; 0.1 M Na2B4O7 for 2 min; TritonX-100 solution for 5 min; 100% normal rabbit and goat serum for 30 min; FITC conjugated BrdU antibody, Tritc conjugated NeuN or Tritc conjugated Nestin antibody for 1 h.

2.8. RNA isolation and RT-PCR analysis {#s0050}
--------------------------------------

In order to isolate RNA, the spinal cord tissue (T8-T10) was harvested and homogenized with 1 mL Tri-reagent (Sigma, St. Louis, MO, USA). The RNA was reverse transcribed with oligo (dT) 15 primers and SuperScript II reverse transcriptase. The reaction mixture was used as a previously reported PCR templates ([@b0090]). Oct4 Forward: Δ-17 FAD gene sequences has been retrieved from NCBI (FW362214.1) as follows 5-ATGGCGACTAAGCAGCCGTAC-3 Reverse: 3-CAGTTCCCGACCCTGACGGAG-5; GFAP Forward: 5-ATCAAGCGGTCGCTGCCCAGC-3; Reverse: 3-GAGTGCTTTGAGGCCTCGGTG-5; MAP2 Forward: 5-CCGCTGTCGCTCTACTACACG-3; Reverse: 3-GTGCGCATCGTGGCCATCGCC-5.

2.9. Statistics {#s0055}
---------------

The SPSS software was used to perform statistics analysis. Data were presented as mean ± SEM. One-way ANOVA was performed to analyze statistical significance. When p values were \<0.05, the differences were considered statistically significant.

3. Results {#s0060}
==========

3.1. The effects of melatonin on motor function recovery {#s0065}
--------------------------------------------------------

All rats showed complete flaccid paralysis within the acute phase of SCI. Then, all groups improved until the end of experiment.

On 14th and 21st days after SCI, compared with those in the SCI and control groups (4.5 ± 1.4, 7.7 ± 1.7 and 4.5 ± 1.5, 7.8 ± 1.8, respectively), BBB score in the melatonin treatment group was significantly higher (8.7 ± 1.7, 11.7 ± 1.5, respectively) ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1The effects of melatonin on motor function recovery. Data were expressed as means ± S.D. (n = 4). ^\*^P \< 0.05, compared with the SCI and control groups, ^\*\*^P \< 0.01, compared with the SCI and control groups.

3.2. The effects of melatonin on eNSPCs proliferation {#s0070}
-----------------------------------------------------

We further assessed the effects of melatonin on eNSPCs proliferation using flow cytometry. On day 1, 7, 14, and 21, rats in the melatonin group showed significantly higher values of BrdU-positive expression indicating significantly higher eNSPCs proliferation. However, on day 3, there was no statistically significant differences observed between groups ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2The effects of melatonin on eNSPCs proliferation. Data were expressed as means ± S.D. (n = 4). ^\*^P \< 0.05, compared with the SCI and control groups, ^\*\*^P \< 0.01, compared with the SCI and control groups.

3.3. The effects of melatonin on Nestin and NeuN expression {#s0075}
-----------------------------------------------------------

In addition, we used immunohistochemistry to assess the effects of melatonin on Nestin and NeuN expression. The results showed that on day 1, 7, 14, and 21, the Nestin and NeuN expression in the melatonin treatment group was significantly higher than those in the SCI and control groups. [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"}.Fig. 3Spinal cord tissue slides were stained with DAB and hematoxylin (positive area brown, nucleus blue). The representative Nestin was stained in the posterior funiculus of spinal cord of rats (ob.40×). A representative NeuN staining of the ventral horn of the rat (ob.20×). Positive staining was located in the cytoplasm and nucleus.Table 1Nestin immunohistochemistry IOD results.GroupsDay 1Day 3Day 7Day 14Day 21SCI33,368 ± 2898.345,662 ± 1388.450,365 ± 2476.547,860 ± 1764.545,456 ± 1555.5Melatonin51,733 ± 2879.3[\*\*](#tblfn2){ref-type="table-fn"}51,370 ± 2037.562,972 ± 2462.3[\*\*](#tblfn2){ref-type="table-fn"}53,873 ± 2366.6[\*](#tblfn1){ref-type="table-fn"}52,456 ± 2366.3[\*](#tblfn1){ref-type="table-fn"}Control34,289 ± 2449.245,300 ± 2344.445,707 ± 2145.144,456 ± 2455.144,796 ± 2048.6[^1][^2][^3]Table 2NeuN immunohistochemistry IOD results.GroupsDay 1Day 3Day 7Day 14Day 21SCI13.7 ± 2.45217.1 ± 3.64913.3 ± 2.04517.3 ± 3.64517.4 ± 2.565Melatonin17.7 ± 3.496[\*](#tblfn3){ref-type="table-fn"}21.4 ± 2.03738.2 ± 3.651[\*\*](#tblfn4){ref-type="table-fn"}37.3 ± 2.367[\*\*](#tblfn4){ref-type="table-fn"}45.6 ± 2366.3[\*\*](#tblfn4){ref-type="table-fn"}Control11.5 ± 2.00715.3 ± 2.34417.1 ± 2.14515.6 ± 2.45517.6 ± 2.048[^4][^5][^6]

3.4. The effects of melatonin on Oct4, MAP2 and GFAP expressions {#s0080}
----------------------------------------------------------------

In addition, we used RT-PCR to study Oct4, MAP2 and GFAP expression at mRNA level. On day 21, compared with Oct4, MAP2 and GFAP expressions in the SCI and control group, those in the melatonin treatment group were significantly higher ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4The effects of melatonin on endogenous neural stem/progenitor cells proliferation after SCI. Oct4 (A), MAP2 (B), and GFAP (C) expression were evaluated by RT-PCR analysis. (A--C; left panels). Densitometry analysis of band intensity in RT-PCR (A--C; right panels). ^\*^P \< 0.05, compared with the SCI and control groups, ^\*\*^P \< 0.01, compared with the SCI and control groups.

4. Discussion {#s0085}
=============

The previous study has shown that SCI results in severe inflammation and compromised endogenous neural stem/progenitor cells regeneration which is the underlying mechanisms of difficulty with functional recovery for patients with SCI ([@b0020], [@b0115], [@b0045]). In the present study, we used trauma-induced SCI rat mode to study the therapeutic effects of melatonin on functional recovery and eNSPCs proliferation and differentiation after SCI.

Our data showed that melatonin induced eNSPCs proliferation at the acute phase of SCI lasting into chronic phase, indicated by BrdU flow cytometry assay. Compared with those in the SCI and control groups, the proliferative activity in the melatonin treatment group was more significant. In addition, we used immunohistochemistry to assess the effects of melatonin on Nestin and NeuN expression, which indicated neural connections and synaptic signal transduction. The results showed that on day 1, 7, 14, and 21, compared with Nestin and NeuN expressions in the SCI and control groups, those in the melatonin treatment group was significantly higher, suggesting melatonin can promote endogenous proliferative activity of eNSPCs.

In addition, we used BBB score to assess melatonin effects on functional recovery after SCI. Our data showed that, at the chronic phase of SCI, the melatonin treatment group had a significantly higher BBB score compared with the SCI group and the control group, which was consistent with the quantitative increase in eNSPCs proliferative activity indicated by BrdU-positive cells and qualitative reconstruction indicated by Nestin and NeuN-expressing cells. For the first time, our results suggested that melatonin treatment promoted eNSPCs proliferation and differentiation after SCI, therefor resulting in prompt functional recovery.

However, the underlying mechanisms participating in melatonin effects on the proliferation and differentiation of eNSPCs after SCI still need to be elucidated. It is reasonable for us to hypothesize that the melatonin receptors may play a role in its effects. The previous study has shown that there are melatonin receptors MT1 and MT2 in spinal cord ([@b0030], [@b0135], [@b0140]). Melatonin binds with MT1 and MT2 to regulate cell metabolism and proliferation by activating insulin and the IGF-1 signaling cascade ([@b0085]). The cell survival and neuronal differentiation were regulated by MT1 and MT2 as well ([@b0065], [@b0060]).

In the present study, we studied Oct4, MAP2, and GFAP, which are markers for mature neurons. We found that the melatonin treatment group had significantly higher expression of Oct4, MAP2, and GFAP on day 21, suggesting that differentiation of eNSPCs into mature neurons is not completed until the chronic phase of SCI. [@b0025] have shown that, after SCI, transplanted neural stem cells differentiated into mature neurons in perilesional sites.

5. Conclusions {#s0090}
==============

The present study showed that melatonin can promote functional recovery and eNSPCs proliferation in SCI rat model. In addition, melatonin significantly increased nestin-positive eNSPCs, indicating that melatonin can promote eNSPCs differentiation. Our results suggested that melatonin is a treatment option for patients with SCI due to its activating effects on adult neural stem cells in CNS.
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[^1]: The values of figure are means ± S.D. (n = 10 rats/group; 5 sections/rat).

[^2]: P \< 0.05, compared with the SCI and control groups.

[^3]: P \< 0.01, compared with the SCI and control groups.

[^4]: The values of figure are means ± S.D. (n = 10 rats/group; 5 sections/rat).

[^5]: P \< 0.05, compared with the SCI and control groups.

[^6]: P \< 0.01, compared with the SCI and control groups.
